Cadence Bank Announces Increase in Quarterly Common Dividend; Declares Preferred Dividend
- 42
PR Newswire
TUPELO, Miss. and HOUSTON, Jan. 25, 2023
TUPELO, Miss. and HOUSTON, Jan. 25, 2023 /PRNewswire/ -- At its meeting today, the board of directors of Cadence Bank (NYSE: CADE) (Cadence) declared a quarterly cash dividend of $0.235 per share of common stock, which represents an increase of $0.015, or 6.8%, per share compared to the previous quarterly dividend of $0.22 per common share. The common stock dividend is payable on April 3, 2023, to shareholders of record at the close of business on March 15, 2023.
The board of directors also declared a quarterly cash dividend of $0.34375 per share of Series A Preferred Stock. The preferred stock dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 3, 2023.
Cadence will report financial results for the fourth quarter of 2022 after the close of the financial markets on January 30, 2023.
Cadence Bank (NYSE: CADE) is a leading regional banking franchise with approximately $50 billion in assets and approximately 400 branch locations across the South and Texas. Cadence provides consumers, businesses and corporations with a full range of innovative banking and financial solutions. Services and products include consumer banking, consumer loans, mortgages, home equity lines and loans, credit cards, commercial and business banking, treasury management, specialized lending, asset-based lending, commercial real estate, equipment financing, correspondent banking, SBA lending, foreign exchange, wealth management, investment and trust services, financial planning, retirement plan management, and personal and business insurance. Cadence is committed to a culture of respect, diversity and inclusion in both its workplace and communities. Cadence Bank, Member FDIC. Equal Housing Lender.
View original content:https://www.prnewswire.com/news-releases/cadence-bank-announces-increase-in-quarterly-common-dividend-declares-preferred-dividend-301730917.html
SOURCE Cadence Bank
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™
- ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT
- Chengdu exhibition paves way for international business
- Every Dollar Lost to Fraud in Australia Costs Firms AUD$3.68 According to LexisNexis True Cost of Fraud Study
- FranklinWH and MMEM Greentech Announce Strategic Partnership to Revolutionize Home Energy Management
- Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023